THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  05/27 04:00:02 pm EDT
572.35 USD   +5.97%
05/23Thermo Fisher Scientific and Qatar Genome Program Announce Partnership to Advance Precision Medicine
CI
05/19THERMO FISHER SCIENTIFIC INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/19Thermo Fisher Scientific Maintains Quarterly Dividend at $0.30 a Share, Payable July 15 to Shareholders as of June 15
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology

01/18/2022 | 04:05pm EDT

Oncocyte Corporation announced a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s Ion Torrent™ Genexus™ System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System. Under the terms of the collaboration, Oncocyte will clinically validate Thermo Fisher’s existing Oncomine Comprehensive Assay Plus* on the Genexus System, paving the way toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic. As an IVD, the >500-gene assay will initially be able to provide physicians with information about patients’ tumors in accordance with established clinical evidence, applicable clinical trials, and future approval may assist with the selection of targeted therapies. Oncocyte will also develop its 27-gene expression DetermaIO™ test as a distributed kit on the Genexus. DetermaIO may predict response to immuno-oncology therapies based on data demonstrating potential pan-cancer utility and improvement over current standard-of-care tests.


© S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
05/23Thermo Fisher Scientific and Qatar Genome Program Announce Partnership to Advance Preci..
CI
05/19THERMO FISHER SCIENTIFIC INC. : Submission of Matters to a Vote of Security Holders (form ..
AQ
05/19Thermo Fisher Scientific Maintains Quarterly Dividend at $0.30 a Share, Payable July 15..
MT
05/19Thermo Fisher Scientific Declares Quarterly Dividend
BU
05/19Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2022
CI
05/19Thermo Fisher Scientific and LabShares Newton Partner to Support Emerging Boston Biotec..
CI
05/18TRANSCRIPT : Thermo Fisher Scientific Inc. - Analyst/Investor Day
CI
05/11TRANSCRIPT : Thermo Fisher Scientific Inc. Presents at Bank of America 2022 Healthcare Con..
CI
05/11IonPath, Inc. announced that it has received funding from Thermo Fisher Scientific Inc.
CI
05/10Thermo Fisher Scientific Introduces QualTrak Biopharma qPCR Solutions to Streamline Bio..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 42 473 M - -
Net income 2022 6 880 M - -
Net Debt 2022 25 212 M - -
P/E ratio 2022 33,0x
Yield 2022 0,21%
Capitalization 224 B 224 B -
EV / Sales 2022 5,87x
EV / Sales 2023 5,57x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 572,35 $
Average target price 668,21 $
Spread / Average Target 16,7%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-19.05%224 053
DANAHER CORPORATION-19.00%190 779
INTUITIVE SURGICAL, INC.-36.22%82 258
SIEMENS HEALTHINEERS AG-14.49%67 624
EDWARDS LIFESCIENCES CORPORATION-21.95%62 872
BOSTON SCIENTIFIC CORPORATION-3.01%58 898